Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field

Tomoyasu Ito, Akihito Nagahara, Taro Osada, Junko Kato, Hiroya Ueyama, Hiroaki Saito, Nobuhito Taniki, Ryo Kanazawa, Ryo Shimizu, Jinkan Sai, Shuichiro Shiina, Sumio Watanabe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Recombinant human soluble thrombomodulin (rTM) was approved recently and has been used for treatment of disseminated intravascular coagulation (DIC). The aim of the present study was to evaluate the efficacy of rTM for DIC. The data of 53 inpatients with sepsis-induced DIC were retrospectively analyzed. Patients were classified into the rTM treatment group (n=25) and conventional treatment group (rTM not used) was the control group (n=28). Diagnosis of DIC was made according to the criteria for acute DIC of the Japan Association of Acute Medicine. Platelet count, prothrombin time-international normalized ratio, levels of fibrin/fibrinogen degradation products (FDP), C-reactive protein and DIC scores were measured on days 0, 3 and 7. Furthermore, the DIC resolution rate was assessed on days 3 and 7. Prior to treatment, DIC scores were 5.0±1.0 in the rTM group and 5.9±1.3 in the control group (P<0.05). Significant intra-group improvements were observed in all the parameters, except for FDP in the two groups. Significant improvements were observed in the DIC scores in the rTM group (Δ2.0±1.9 vs. Δ1.5±1.9, P=0.001). Therefore, the results suggest that rTM would be a useful medicine for treatment of DIC in the gastroenterology field.

Original languageEnglish
Pages (from-to)457-460
Number of pages4
JournalBiomedical Reports
Volume3
Issue number4
DOIs
Publication statusPublished - 2015 Jul 1
Externally publishedYes

Fingerprint

Gastroenterology
Thrombomodulin
Disseminated Intravascular Coagulation
Coagulation
Sepsis
Medicine
human THBD protein
Fibrin Fibrinogen Degradation Products
Therapeutics
Control Groups
International Normalized Ratio
Prothrombin Time
Prothrombin
Platelets
Platelet Count
C-Reactive Protein
Fibrinogen
Inpatients

Keywords

  • Cholangitis
  • Disseminated intravascular coagulation
  • Gabexate mesilate
  • Recombinant human soluble thrombomodulin
  • Sepsis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field. / Ito, Tomoyasu; Nagahara, Akihito; Osada, Taro; Kato, Junko; Ueyama, Hiroya; Saito, Hiroaki; Taniki, Nobuhito; Kanazawa, Ryo; Shimizu, Ryo; Sai, Jinkan; Shiina, Shuichiro; Watanabe, Sumio.

In: Biomedical Reports, Vol. 3, No. 4, 01.07.2015, p. 457-460.

Research output: Contribution to journalArticle

Ito, T, Nagahara, A, Osada, T, Kato, J, Ueyama, H, Saito, H, Taniki, N, Kanazawa, R, Shimizu, R, Sai, J, Shiina, S & Watanabe, S 2015, 'Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field', Biomedical Reports, vol. 3, no. 4, pp. 457-460. https://doi.org/10.3892/br.2015.464
Ito, Tomoyasu ; Nagahara, Akihito ; Osada, Taro ; Kato, Junko ; Ueyama, Hiroya ; Saito, Hiroaki ; Taniki, Nobuhito ; Kanazawa, Ryo ; Shimizu, Ryo ; Sai, Jinkan ; Shiina, Shuichiro ; Watanabe, Sumio. / Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field. In: Biomedical Reports. 2015 ; Vol. 3, No. 4. pp. 457-460.
@article{1f9ce34eff9e4ab0a0f9cb2729b73ab6,
title = "Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field",
abstract = "Recombinant human soluble thrombomodulin (rTM) was approved recently and has been used for treatment of disseminated intravascular coagulation (DIC). The aim of the present study was to evaluate the efficacy of rTM for DIC. The data of 53 inpatients with sepsis-induced DIC were retrospectively analyzed. Patients were classified into the rTM treatment group (n=25) and conventional treatment group (rTM not used) was the control group (n=28). Diagnosis of DIC was made according to the criteria for acute DIC of the Japan Association of Acute Medicine. Platelet count, prothrombin time-international normalized ratio, levels of fibrin/fibrinogen degradation products (FDP), C-reactive protein and DIC scores were measured on days 0, 3 and 7. Furthermore, the DIC resolution rate was assessed on days 3 and 7. Prior to treatment, DIC scores were 5.0±1.0 in the rTM group and 5.9±1.3 in the control group (P<0.05). Significant intra-group improvements were observed in all the parameters, except for FDP in the two groups. Significant improvements were observed in the DIC scores in the rTM group (Δ2.0±1.9 vs. Δ1.5±1.9, P=0.001). Therefore, the results suggest that rTM would be a useful medicine for treatment of DIC in the gastroenterology field.",
keywords = "Cholangitis, Disseminated intravascular coagulation, Gabexate mesilate, Recombinant human soluble thrombomodulin, Sepsis",
author = "Tomoyasu Ito and Akihito Nagahara and Taro Osada and Junko Kato and Hiroya Ueyama and Hiroaki Saito and Nobuhito Taniki and Ryo Kanazawa and Ryo Shimizu and Jinkan Sai and Shuichiro Shiina and Sumio Watanabe",
year = "2015",
month = "7",
day = "1",
doi = "10.3892/br.2015.464",
language = "English",
volume = "3",
pages = "457--460",
journal = "Biomedical Reports",
issn = "2049-9434",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field

AU - Ito, Tomoyasu

AU - Nagahara, Akihito

AU - Osada, Taro

AU - Kato, Junko

AU - Ueyama, Hiroya

AU - Saito, Hiroaki

AU - Taniki, Nobuhito

AU - Kanazawa, Ryo

AU - Shimizu, Ryo

AU - Sai, Jinkan

AU - Shiina, Shuichiro

AU - Watanabe, Sumio

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Recombinant human soluble thrombomodulin (rTM) was approved recently and has been used for treatment of disseminated intravascular coagulation (DIC). The aim of the present study was to evaluate the efficacy of rTM for DIC. The data of 53 inpatients with sepsis-induced DIC were retrospectively analyzed. Patients were classified into the rTM treatment group (n=25) and conventional treatment group (rTM not used) was the control group (n=28). Diagnosis of DIC was made according to the criteria for acute DIC of the Japan Association of Acute Medicine. Platelet count, prothrombin time-international normalized ratio, levels of fibrin/fibrinogen degradation products (FDP), C-reactive protein and DIC scores were measured on days 0, 3 and 7. Furthermore, the DIC resolution rate was assessed on days 3 and 7. Prior to treatment, DIC scores were 5.0±1.0 in the rTM group and 5.9±1.3 in the control group (P<0.05). Significant intra-group improvements were observed in all the parameters, except for FDP in the two groups. Significant improvements were observed in the DIC scores in the rTM group (Δ2.0±1.9 vs. Δ1.5±1.9, P=0.001). Therefore, the results suggest that rTM would be a useful medicine for treatment of DIC in the gastroenterology field.

AB - Recombinant human soluble thrombomodulin (rTM) was approved recently and has been used for treatment of disseminated intravascular coagulation (DIC). The aim of the present study was to evaluate the efficacy of rTM for DIC. The data of 53 inpatients with sepsis-induced DIC were retrospectively analyzed. Patients were classified into the rTM treatment group (n=25) and conventional treatment group (rTM not used) was the control group (n=28). Diagnosis of DIC was made according to the criteria for acute DIC of the Japan Association of Acute Medicine. Platelet count, prothrombin time-international normalized ratio, levels of fibrin/fibrinogen degradation products (FDP), C-reactive protein and DIC scores were measured on days 0, 3 and 7. Furthermore, the DIC resolution rate was assessed on days 3 and 7. Prior to treatment, DIC scores were 5.0±1.0 in the rTM group and 5.9±1.3 in the control group (P<0.05). Significant intra-group improvements were observed in all the parameters, except for FDP in the two groups. Significant improvements were observed in the DIC scores in the rTM group (Δ2.0±1.9 vs. Δ1.5±1.9, P=0.001). Therefore, the results suggest that rTM would be a useful medicine for treatment of DIC in the gastroenterology field.

KW - Cholangitis

KW - Disseminated intravascular coagulation

KW - Gabexate mesilate

KW - Recombinant human soluble thrombomodulin

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=85011609028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011609028&partnerID=8YFLogxK

U2 - 10.3892/br.2015.464

DO - 10.3892/br.2015.464

M3 - Article

AN - SCOPUS:85011609028

VL - 3

SP - 457

EP - 460

JO - Biomedical Reports

JF - Biomedical Reports

SN - 2049-9434

IS - 4

ER -